New research has identified a possible way to manipulate certain stem cells to generate new bone tissue. The results of this investigation could vastly improve the outcome for people with skeletal injuries or conditions such as osteoporosis.
Stem cells are
undifferentiated cells that have the potential to specialize and undertake any
function.
Much
recent research has focused on how best to use stem cells for therapeutic
purposes. Researchers are particularly interested in how to manipulate them to
create new tissue that can successfully replace damaged sets of cells or those
that are no longer functional.
In a
new study from the Johns Hopkins University School of Medicine in Baltimore,
MD, Dr. Aaron James and his team have looked into the mechanisms that allow
certain types of stem cell, which are known as "perivascular stem cells," to form new bone tissue.
These
stem cells tend to turn into either fat tissue or bone tissue. To date, it has
been unclear what, exactly, determines their fate.
"Our
bones have a limited pool of stem cells to draw from to create new bone. If we
could coax these cells toward a bone cell fate and away from fat, it would be a
great advancement in our ability to promote bone health and healing."
Dr. Aaron James
The
investigators conducted their research in a rat model as well as in human cell
cultures, and they report their findings in the journal Scientific Reports.
The
protein that drives cell fate
Previous
studies that Dr. James conducted have suggested that a particular signaling
protein called WISP-1 is likely to drive the fate of perivascular stem cells by
"telling" them whether to form fat or bone tissue.
In the
current study, the researchers sought to prove WISP-1's role in determining
stem cell fate by genetically modifying a set of human stem cells to stop them
from producing this protein.
When they compared gene activity in the
engineered stem cells with gene activity in cells that still produced WISP-1,
the researchers confirmed that the protein played an important role. In the
cells without WISP-1, four of the genes responsible for fat formation had a
50–200 percent higher level of activity than they did in the cells continuing
to produce WISP-1.
This
also indicated that the correct dosage of this signaling protein could drive
the stem cells to form bone tissue instead of fat tissue.
As
expected, when the researchers then modified stem cells to increase WISP-1
production, they noticed that three of the genes that stimulate bone tissue
growth became twice as active compared with those in stem cells with normal
levels of the signaling protein.
At the
same time, the activity of genes that stimulated the growth of fat tissue —
such as peroxisome proliferator-activated receptor gamma (PPARG) — was 42
percent lower in stem cells with a WISP-1 boost, and this decrease occurred in
favor of genes that determine bone tissue growth.
Stem
cell intervention shows promise
In the
next stage of the study, the scientists used a rat model to determine whether
WISP-1 could boost bone healing in spinal fusion, a type of medical
intervention that requires joining two or more vertebrae (spine bones) to form
a single bone.
The
therapeutic use of spinal fusion is to improve back pain or
spinal stability in the context of various conditions that affect the spine,
such as scoliosis.
Usually,
"Such a procedure requires a massive amount of new bone cells,"
explains Dr. James. "If we could direct bone cell creation at the site of
the fusion, we could help patients recover more quickly and reduce the risk of
complications," he notes.
In the
current study, the researchers injected human stem cells that had active WISP-1
into rats. They did this between the vertebrae that were due to become joined
as part of the fusion procedure.
After 4 weeks, Dr. James and his team found
that the animals still displayed high levels of WISP-1 in their spinal tissue.
Moreover, new bone tissue was already forming in the right places, allowing the
vertebrae to become "welded."
Conversely,
rats that had received the same surgical intervention but without the WISP-1
boost did not present any vertebral fusion during this same period.
"We
hope our findings will advance the development of cellular therapies to promote
bone formation after surgeries like this one and for other skeletal injuries
and diseases, such as broken bones and osteoporosis,"
Dr. James declares.
In the
future, the research team also aims to find out whether reducing WISP-1 levels
in stem cells could lead them to form fat tissue, which could help promote
faster wound healing.
No comments:
Post a Comment